These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1895280)

  • 21. [Disturbances in humoral immunity and immunomodulation in patients with peritonitis].
    Stoĭkov D; Ignatov K; Andreeva Kh; Petrova P
    Khirurgiia (Sofiia); 2001; 57(3-4):22-4. PubMed ID: 12024667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient characteristics and intravenous immunoglobulin product may affect eosinophils in Kawasaki disease.
    Kuo HC; Wang CL; Wang L; Yu HR; Yang KD
    Pediatr Allergy Immunol; 2008 Mar; 19(2):184-5. PubMed ID: 18257906
    [No Abstract]   [Full Text] [Related]  

  • 23. Anticomplementary activity and the safety of intravenous immunoglobulin.
    Rousell RH; Budinger MD; Keppler DC; Victor R; Minaga T
    Clin Ther; 1989; 11(1):143-50. PubMed ID: 2497981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Use of high doses of intravenous immunoglobulin in the treatment of neonatal thrombocytopenia secondary to maternal idiopathic thrombopenic purpura].
    García-Monge Santidrian S; Hawkins Carranza F; Arroyo Carrera I; Muro Brussi M; Sacristán Martín A; Cabañas González F; Escribá Polo R; Magallón Martínez M; Quero Jiménez J
    An Esp Pediatr; 1988 Oct; 29(4):333-4. PubMed ID: 3232883
    [No Abstract]   [Full Text] [Related]  

  • 25. Intravenous immunoglobulin in Kawasaki syndrome: a progress report.
    Melish ME
    Pediatr Infect Dis; 1986; 5(3 Suppl):S211-5. PubMed ID: 3487077
    [No Abstract]   [Full Text] [Related]  

  • 26. [Present status of high-dose intravenous immunoglobulin therapy and the future prospects ].
    Kawasugi K
    Nihon Rinsho Meneki Gakkai Kaishi; 2003 Jun; 26(3):87-95. PubMed ID: 12868126
    [No Abstract]   [Full Text] [Related]  

  • 27. High-dose intravenous gamma globulin therapy for immune thrombocytopenia.
    Reding D; Amare M
    Wis Med J; 1988 Feb; 87(2):11-3. PubMed ID: 3126604
    [No Abstract]   [Full Text] [Related]  

  • 28. [Immunoregulatory mechanisms of action of intravenous gammaglobulin in Kawasaki syndrome].
    Marcinkiewicz J; Szymanowska Z; Mazurek A
    Przegl Lek; 1998; 55(11):611-3. PubMed ID: 10216377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Kawasaki disease.
    Taddio A; Rosé CD
    N Engl J Med; 2007 Jun; 356(26):2747; author reply 2748. PubMed ID: 17600908
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice.
    Nicoletti A; Kaveri S; Caligiuri G; Bariéty J; Hansson GK
    J Clin Invest; 1998 Sep; 102(5):910-8. PubMed ID: 9727059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Kawasaki syndrome in adults: treatment with polyvalent intravenous immunoglobulins].
    Pavese P; Brion JP; Meusnier T; Stahl JP
    Ann Med Interne (Paris); 1997; 148(3):287-8. PubMed ID: 9255342
    [No Abstract]   [Full Text] [Related]  

  • 32. Starch microparticles as an adjuvant in immunisation: effect of route of administration on the immune response in mice.
    Stertman L; Strindelius L; Sjöholm I
    Vaccine; 2004 Jul; 22(21-22):2863-72. PubMed ID: 15246622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin.
    Gordon DJ; Sloan SR; de Jong JL
    Am J Hematol; 2009 Nov; 84(11):771-2. PubMed ID: 19806664
    [No Abstract]   [Full Text] [Related]  

  • 34. Experience with sandoglobulin in bone marrow transplantation.
    Tutschka PJ; Copelan EA
    Int J Cell Cloning; 1986; 4 Suppl 1():181-8. PubMed ID: 3018102
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis.
    Norrby-Teglund A; Haque KN; Hammarström L
    J Intern Med; 2006 Dec; 260(6):509-16. PubMed ID: 17116001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease.
    Khan S; Doré PC; Sewell WA
    Pediatr Allergy Immunol; 2008 Mar; 19(2):186-7. PubMed ID: 18257907
    [No Abstract]   [Full Text] [Related]  

  • 38. [Stimulation of the nonspecific resistance by beta-heptylglycoside-muramyldipeptide in mice].
    Kaliuzhin OV; Kaliuzhin VV; Zemliakov AE; Elkina SI; Shkalev MV; Sergeev VV
    Biull Eksp Biol Med; 1999 May; 127(5):543-5. PubMed ID: 10399577
    [No Abstract]   [Full Text] [Related]  

  • 39. Differential expression and cross-regulatory function of RANTES during mycobacterial (type 1) and schistosomal (type 2) antigen-elicited granulomatous inflammation.
    Chensue SW; Warmington KS; Allenspach EJ; Lu B; Gerard C; Kunkel SL; Lukacs NW
    J Immunol; 1999 Jul; 163(1):165-73. PubMed ID: 10384113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thymopentin in the treatment of alopecia areata.
    Orecchia G
    Dermatologica; 1989; 178(4):231. PubMed ID: 2670621
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.